CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
CNS Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
CNS Pharmaceuticals | 8-K/A: Current report (Amendment)
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K/A: Current report (Amendment)
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025
No Data
No Data